Safety Studies for Use of Adipose Tissue-Derived Mesenchymal Stromal/Stem Cells in a Rabbit Model for Osteoarthritis to Support a Phase I Clinical Trial
Scott M. Riester, Janet M. Denbeigh, Yang Lin, Dakota L. Jones, Tristan de Mooij, Eric A. Lewallen, Hai Nie, Christopher R. Paradise, Darcie J. Radel, Amel Dudakovic, Emily T. Camilleri, Dirk R. Larson, Wenchun Qu, Aaron J. Krych, Matthew A. Frick, Hee-Jeong Im, Allan B. Dietz, Jay Smith, Andre J. van Wijnen
Abstract
: Adipose-derived mesenchymal stem cells (AMSCs) offer potential as a therapeutic option for clinical applications in musculoskeletal regenerative medicine because of their immunomodulatory functions and capacity for trilineage differentiation. In preparation for a phase I clinical trial using AMSCs to treat patients with osteoarthritis, we carried out preclinical studies to assess the safety of human AMSCs within the intra-articular joint space. Culture-expanded human AMSCs grown in human platelet-lysate were delivered via intra-articular injections into normal healthy rabbit knees and knees at risk for the development of osteoarthritis after bilateral medial anterior hemimeniscectomy. Treatment outcomes and safety were evaluated by assessing the general health, function, and behavior of the animals. Joint tissues were analyzed by x-ray, magnetic resonance imaging, and histopathology. Intra-articular AMSC therapy was well tolerated in this study. We did not observe adverse systemic reactions, nor did we find evidence of damage to intra-articular joint tissues. Thus, the data generated in this study show a favorable safety profile for AMSCs within the joint space in support of a phase I clinical trial evaluating the clinical utility of AMSCs to treat osteoarthritis.
This safety study indicates that adipose-derived mesenchymal stem cells (AMSCs) can be safely used in cell therapies for joint degeneration. This finding supports a phase I clinical trial to evaluate the clinical utility of AMSCs in treating osteoarthritis.
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 December 2018.
All research outputs
#7,245,857
of 22,896,955 outputs
Outputs from Stem Cells Translational Medicine
#818
of 1,518 outputs
Outputs of similar age
#110,135
of 314,045 outputs
Outputs of similar age from Stem Cells Translational Medicine
#20
of 46 outputs
Altmetric has tracked 22,896,955 research outputs across all sources so far. This one has received more attention than most of these and is in the 67th percentile.
So far Altmetric has tracked 1,518 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 20.5. This one is in the 44th percentile – i.e., 44% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 314,045 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 64% of its contemporaries.
We're also able to compare this research output to 46 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 56% of its contemporaries.
